Alphabet’s Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis

Isomorphic Labs, a unit of Google-parent Alphabet (GOOGL), on Sunday announced strategic research collaborations with Eli Lilly (LLY) and Novartis (NVS). The Lilly and Novartis collaborations will focus on small-molecule treatments and multiple targets. Isomorphic Labs, which uses artificial intelligence to help discover new drugs, will receive upfront cash and possible milestone payments.

X

Eli Lilly and Isomorphic Labs will team up to discover small molecule therapeutics for multiple targets. Isomorphic will receive $45 million upfront, with up to $1.7 billion in milestone payments as well as possible royalties.

The Novartis-Isomorphic collaboration will focus on finding small molecule therapeutics vs. three targets. Alphabet’s Isomorphic gets $37.5 million cash now, along with Novartis covering some research costs. It’s als0 eligible for up to $1.2 billion in milestone payments, plus possible royalties.

Stocks

Eli Lilly stock leapt 6.1% to 618.55 last week, clearing early entries on Tuesday and Wednesday. On Thursday, LLY stock briefly topped a 629.97 flat-base buy point.

NVS stock jumped 5.3% last week to 106.31. Shares are now extended from a double-bottom buy point of 98.69, decisively cleared in the final days of last year.

GOOGL stock sank 2.8% to 135.73, falling below a 139.42 cup-with-handle buy point and testing support at the 10-week line.

Please follow Ed Carson on Threads at @edcarson1971, X/Twitter at @IBD_ECarson and Bluesky at @edcarson.bsky.social for stock market updates and more.

YOU MIGHT ALSO LIKE:

Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader

Best Growth Stocks To Buy And Watch

IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today

Bitcoin ETFs Are Coming Fast. Crypto Investing Will Never Be The Same.

It’s Been An Abysmal Two Years. But Biotech Is Looking Up.

Futures Loom; Nvidia Leads Six Stocks To Watch